Pages
News
Press releases
Publications
CLCC
Jobs
Expert groups
Clinical trials
- Phase III randomised study to evaluate the benefit of adjuvant hormonal treatment with leuprorelin acetate (eligard® 45mg) for 24 months after radical prostatectomy in patients with high risk of recurrence.
- Prospective multicenter study assessing EndoPredict® (EPClin) genomic test impact on shared decision of adjuvant chemotherapy in patients with ER-positive, Her2-negative early breast cancer with uncertainty on the indication of chemotherapy using standard assessments
- Secured access to nivolumab for adult patients with selected rare cancer types
- Phase II / III study comparing radiochemotherapy with the folfox regimen versus radiochemotherapy with 5fu-cisplatin (herskovic regimen) in first line treatment of patients with inoperable oesophageal cancer
- Essai de phase II multicentrique étudiant l’impact de la séquence thérapeutique radiochimiothérapie pré opératoire (50 Gy + capecitabine + oxaliplatine + cetuximab) suivie d’une chirurgie TME puis d’une chimiothérapie post opératoire (Folfox 4 + cetuximab) dans les cancers du rectum localement avancés métastatiques synchrones avec métastases résécables d’emblée (T3-4 Nx ou T2 N+ M1)
- Essai de phase III comparant une chimiothérapie par 5FU+Streptozocine à une immunothérapie par Interféron alpha2-a recombinant (Roféron) dans le traitement des tumeurs carcinoïdes métastatiques
- Intensification thérapeutique des cancers epidermoïdes du canal anal localement avancés : essai de phase Ill
- Conformal curative radiotherapy of cancer located in the prostate (N0, N-): A multicentric phase III study of the contribution to survival without biological or clinical evolution of a dose increase of 15% (80 Gy VERSUS 70 Gy).
- Internation study for the salvage treatment of germ cell tumours (Etude Internationale de traitement des tumeurs germinales non en rémission).
- Protocole de chimiothérapie de rattrapage des formes résistantes au cisplatine des tumeurs germinales : essai de phase II (protocole TAXIF)
- Tumeurs germinales en situation de 2ème rattrapage Protocole VB4- BOP - CISCA - CARBOPEC. Essai de type phase II ouvert.
- Adjuvant systemic treatment for oestrogen-receptor (ER)-positive HER2-negative breast carcinoma in women over 70 according to genomic grade index (GGI): chemotherapy + endocrine treatment versus endocrine treatment. A French Unicancer Geriatric Oncology Group (GERICO) and Breast Group (UCBG) phase III multicentre trial
- A phase II, randomized, multi-center study, assessing value of adding RAD001 to trastuzumab as preoperative therapy of HER-2 positive primary breast cancer amenable to surgery
- Phase 2, Open label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for advanced BreaSt Cancer patients, with biomarkers analysis to characterize response/resistance to therapY
- Open-label, randomized, multicenter, phase III study, comparing standard chemotherapy to Endocrine Therapy + Abemaciclib combination as initial metastatic treatment among patients with visceral metastasis of ER+ Her2- breast cancer, high burden disease
- Phase II study of pazopanib in patients with recurrent and /or metastatic salivary gland carcinoma of the head and neck
- A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant therapy in BRCA mutated high-risk HER2-negative primary breast cancer patients who have completed definitive local and systemic neoadjuvant/adjuvant treatment
- MyPeBS - (Personalizing Breast Screening) International Randomized Study Comparing personalized, Risk-Stratified to Standard Breast Cancer Screening In Women Aged 40-70
- A phase I/II basket trial evaluating a combinaition of Metronomic oral vinorelbine plus antiPD1/PDL1 immunotherapy in patients with advanced solid tumors
- A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH STANDARD ADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH OPERABLE TRIPLE-NEGATIVE BREAST CANCER
- Adjuvant radiotherapy in patients with pathological high-risk bladder cancer: A randomized multicentre phase II study: Bladder-ART study
- Protocole d'étude multicentrique de la qualité de vie chez les patients porteurs de tumeurs de vessie infiltrantes traitées de façon conservatrice par une association de radiothérapie - chimiothérapie.
- Traitement de l'adénocarcinome sarcomatoïde du rein de l'adulte en phase métastatique par association de Doxorubicine et Ifosfamide. Etude de phase II.
- A randomized, phase II study to compare the regorafenib-trifluridine/tipiracil versus trifluridine/tipiracil-regorafenib sequences beyond second-line therapy in patients with metastatic colorectal cancer
- A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE/TAE for patients with intermediate stage HCC
- A randomized phase II trial assessing Regorafenib (Stivarga®) in combination with irinotecan in metastatic gastric cancer patients as 2nd line treatment
- Basket phase II trial evaluating the efficacy of a combination of pembrolizumab and vorinostat in patients with advanced and/or recurrent squamous cell carcinoma
- Phase III study evaluating palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy
- Optimized combined locoregional and systemic treatments for de novo, treatment naive, stage IV ER+, HER2- breast cancer patients
- A randomized prospective multicenter study comparing fibula free-flap mandibular reconstruction with or without preoperative virtual planning in patients with oral or oropharyngeal cancer.
- A Multicentric randomized phase II trial evaluating dual targeting of the EGFR using the combination of cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtRAS (KRAS and NRAS) metastatic colorectal cancer.
- Randomized phase III study comparing preoperative chemoradiotherapy alone versus neoadjuvant chemotherapy with folfirinox regimen followed by preoperative chemoradiotherapy for patients with resectable locally advanced rectal cancer
- A randomized phase 2 study in patients with triple-negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine
- A Randomized Phase II, placebo-controlled , multicenter study evaluating efficacy and safety of regorafenib in patients with metastatic bone sarcomas
- Randomized phase II study studying the efficacy of gemcitabine and the second-line gemcitabine / docetaxel combination in uterine leiomyosarcomas or metastatic and / or relapsed soft tissue relapses
- Multicentric Phase II Study of Sequential Doxorubicin-CDDP-Ifosfamide (API-AI) Chemotherapy of Operable Osteosarcomas in Patients 16 Years and Over
- High Throughput Technologies to Drive Breast Cancer Patients to Specific Phase I/II Trials of Targeted Agents
- Neoadjuvant and adjuvant RIBOciclib and endocrine therapy for cLinicAlly high-RISk estrogen receptor-positive (ER+) and HER2-negative (HER2-) breast cancer
- Essai prospectif randomisé de chimiothérapie d'induction des adénocarcinomes du bas cesophage et de la jonction cardio-tubérositaire par 5FU continu I.V.+ Cisplatine, comparée à la chirurgie première
- Etude de 2eme look (deuxième regard) chirurgical avec ou sans chimiothérapie intrapéritonéale, en cas de risque de recidive intraperitonéale
- Chimiothérapie intra-artérielle hépatique par oxaliplatine associée au LV5FU2 intra-veineux
- Essai de phase Ill randomisé avec intensification de la chimiothérpaie adjuvante dans les cancers du colon réséqués avec au moins quatre ganglions positifs et/ou révélés par une occlusion ou perforation
- Etude de l'efficacite et de la tolérance de l'association Tomudex® + Eloxatine® chez les patients atteints d'un cancer colorectal avancé non prétraités
- Phase II randomized study comparing FOLFIRINOX + Panitumumab versus FOLFOX + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF status from circulating DNA analysis.
- Randomized phase II study of first-line FOLFIRI plus cetuximab for 8 cycles followed by either single-agent cetuximab as maintenance therapy or observation in patients with wild-type KRAS and NRAS metastatic colorectal cancer
- Randomised, phase III study comparing chemotherapy under the Folfirinox protocol to gemcitabine in treatment of locally advanced pancreatic cancer.
- Phase III multicentre randomized study comparing the effect of adjuvant chemotherapy for six months with gemcitabine-oxaliplatin 85 mg/m2 (GEMOX 85) to observation in patients who underwent surgery for cancer of the bile ducts
- Essai de phase II multicentrique non randomisée etudiant l’impact de l’association radiochimiothérapie (65 gy + cisplatine + 5FU) au cetuximab chez les patients présentant un cancer anal localement avancé.
- Phase III study evaluating the uise of systemic chemotherapy and ChemoHyperthemia Intraperitoneal Preoperatively (CHIP) and after maximum resection of peritoneal carcinomatosis originating with colorectal cancer
- Etude de phase II randomisée évaluant l’efficacité et la toxicité de l'association ( bévacizumab + FOLFIRI) et de l'association (bévacizumab + XELIRI) en première ligne de chimiothérapie des patients atteints d’un cancer du colorectal métastatique
- Essai randomisé de phase III comparant l’effet préopératoire de deux schémas de radiochimiothérapie concomitante (45 Gy + capecitabine vs 50 Gy + capecitabine – oxaliplatine) sur la stérilisation de la pièce opératoire dans les cancers résécables du rectum T3-T4 N0-2 M0
- Etude randomisée de phase II comparant
l'association Oxaliplatine / Irinotécan / LV5FU2 (Folfirinox) à la Gemcitabine seule en première ligne de traitement de patients atteints d'un cancer du pancréas métastatique
- Etude randomisée de phase II évaluant l'association RT-docétaxel et l'association RT-docétaxel-cisplatine dans les adénocarcinomes du pancréas localement avancés non résécables
- Etude de phase II/III randomisée évaluant trois chimiothérapies : Irinotécan/Oxaliplatine (irinox), Irinotécan/LV5-FU2 et Oxaliplatine/LV5-FU2 en première ligne de traitement de patients ayant un cancer colorectal métastatique.
- Prospective Phase II Study Evaluating a Multimodal Care of Inguinal Node Metastasis in Squamous Cell Carcinoma of the Penis by Bilateral Lymphadenectomy and Chemotherapy TIP
- Secured access to vemurafenib for patients with tumors harboring BRAF genomic alterations
- Secured access to pembrolizumab for patients with selected rare cancer types
- Secured access to crizotinib for patients with tumors harboring a genomic alteration on one of the biological targets of the drug
- Multicentric randomized phase III trial comparing adjuvant chemotherapy with gemcitabine versus 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (mFolfirinox) in patients with resected pancreatic adenocarcinoma
- Phase II, multicentric randomized trial, evaluating the efficacy of fluoropyrimidine-based standard chemotherapy, associated to either cetuximab or bevacizumab, in KRAS wild-type metastatic colorectal cancer patients with progressive disease after receiving first-line treatment with bevacizumab
- Phase II Multicentric Randomized Trial, Evaluating the Best Protocol of Chemotherapy, Associated With Targeted Therapy According to the Tumour RAS Status (KRAS and NRAS), in Metastatic Colorectal Cancer (MCRC) Patients With Initially Non-resectable Hepatic Metastases.
- Essai de phase II randomisé multicentrique évaluant l’efficacité d’une chimiothérapie seule ou combinée à l’AMG 102 ou au panitumumab en traitement de première ligne chez des patients atteints d’adénocarcinome œsogastrique avancé
- Randomized phase III study evaluating hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse
- Prospective cohort study to identify the predictive factors of response to PD-1 or PD-L1 antagonists
- Choice And Real experience of Therapeutic deEscalation in women over 65 year with breast cancer (CARTE)
- Étude multicentrique de phase II randomisée, évaluant l’efficacité de l’anastrozole et du fulvestrant dans le traitement néo-adjuvant du cancer du sein opérable chez les femmes ménopausées et ayant pour objectif l’identification de profils d’hormonosensibilité.
- A cohort to quantify and to predict treatment related chronic toxicities in patients with non-metastatic breast cancer
- A phase II trial evalutating Abiraterone in molecular apocrine locally advanced or metastatic breast cancer (AMA)
- Phase 2, randomised trial testing the addition of upfront stereotactic radiosurgery to binimetinib, encorafenib plus pembrolizumab in comparison with binimetinib, encorafenib plus pembrolizumab alone in patients with BRAFV600 mutation-positive melanoma with brain metastasis
- An open label, randomized, phase III trial, evaluating efficacy of Atezolizumab in addition to one year BCG (Bacillus CaLmette-Guerin) bladder instillation in BCG-naive patients with high-risk non-muscle invasive Bladder cANcer
- An open label dose Escalation and Pharmacokinetic
Phase I Study with Pazopanib in Combination with Cisplatin (CDDP) every three Weeks
in Patients with advanced solid Tumors
- Retrospective study assessing the concordance of the IHC4 score performed in local pathology laboratory or in a central laboratory to a molecular gold standard test Endopredict in breast cancer infiltrating RH+ HER2-
- Intérêt de la Tomographie par Émission de Positons avec la 3'-désoxy-3’-[18F]fluoro-thymidine ([18F]-FLT) pour l’évaluation de la réponse à la chimiothérapie néoadjuvante des cancers du sein.
- Molecular characterization of patients with solid tumors who presented an exceptional response to targeted therapies
- Serodiagnostic COVID-19 in oncology
- DOLAF- An international multicenter phase I/II trial of Durvalumab plus OLAparib plus Fulvestrant in metastatic or locally advanced ER-positive, HER2-negative breast cancer patients selected using criteria that predict sensitivity to olaparib.
- De-Escalation of adjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER2 blOckade
- Consensus patients pour des recherches en soins de support
- Randomized phase III study of oral cyclophosphamide vs doxorubicin in 65 years or older patients with advanced or metastatic soft tissue sarcoma: a UNICANCER/GERICO multicenter program
- Phase III study evaluating two neoadjuvant treatments, radiochemotherapy (5 weeks - 50Gy + Capecitabine) and radiotherapy (1 week - 25Gy), in patients over 75 years of age with locally advanced rectal adenocarcinoma. PRODIGE-GERICO-GRECCAR study
- Randomized phase II study to assess the feasibility of docetaxel – prednisone chemotherapy on a weekly or every 3 weeks basis in a population of “vulnerable” or “fragile” elderly patients (75 years), defined according to the SIOG criteria, carriers of a metastatic prostate adenocarcinoma refractory to castration and progressive.
- Etude de phase II évaluant l’activité et la tolérance de l’association lapatinib-capécitabine chez le sujet âgé de 70 ans ou plus atteint de cancer du sein métastatique surexprimant HER2
- Essai clinique multicentrique pilote de chimiothérapie adjuvante chez le sujet de 70 ans ou plus : impact sur l’indépendance et la qualité de vie de l’administration d’une chimiothérapie à base d’anthracyclines en situation adjuvante chez des patientes présentant un cancer du sein opérable d’emblée, récepteurs hormonaux négatifs (RH-), avec envahissement ganglionnaire (pN+) ou pN0 mais de grade SBR III et ≥ 2 cm
- Traitement radio-chirurgical du cancer du sein de la femme âgée de plus 70 ans sans envahissement ganglionnaire : étude de phase II multicentrique de la faisabilité et de la reproductibilité d’une radiothérapie concentrée et focalisée
- Etude de phase II d'impact d'une association de chimiothérapie orale : capécitabline Vinorelbine sur le degré d'autonomie dans les activités de la vie quotidienne (ADL de Katz) des patients âgés de plus de 70 ans ayant un adénocarcinome métastatique ou localement avancé, initialement ou en rechute non pré-traitée.
- Dose-escalation, Phase I Multicentric Trial, evaluating the combination of LEE011 and capecitabine in locally advanced or metastatic breast cancer HER2 negative
- Neoadjuvant phase II trial combining [3 FEC 100 followed by 3 docetaxel associated with trastuzumab plus pertuzumab] or [6 docetaxel, carboplatin associated with trastuzumab plus pertuzumab] according to TOP2A status in patients with operable, HER2-positive breast cancer. Identification of pathological Complete Response (pCR) predictive factor
- Safety and efficacy of radiotherapy combined with a 6-month LH-RH agonist and abiraterone hormone therapy treatment in biochemically-relapsing prostate cancer following surgery.
- Phase II, randomized, multicenter study of Afatinib (BIBW2992) administered preoperatively, in patients with squamous cell carcinoma of the upper aerodigestive tract, non metastatic, with a view to identifying predictive and / or pharmacodynamic biomarkers of activity and efficiency
- A RISK-ADAPTED STRATEGY OF THE USE OF DOSE-DENSE CHEMOTHERAPY IN PATIENTS WITH POOR-PROGNOSIS DISSEMINATED NON-SEMINOMATOUS GERM CELL TUMORS: A PHASE III TRIAL
- Phase 3 trial, comparing combined hormonal and chemotherapy treatment (docetaxel and estramustin) with hormonal treatment alone, in a neo-adjuvant situation of prostate cancer that is locally advanced or at high risk of relapse.
- Phase II study of allogeneic intrafamily transplantation in patients with metastatic kidney cancer.
- Randomized phase III trial comparing immediate chemotherapy versus deferred chemotherapy after radical cystectomy in patients with transitional carcinoma (TTC) of the bladder stage pT3-pT4 and / or N + M0
- Randomized phase III study comparing the combination of paclitaxel / cisplatin / gemcitabine versus cisplatin / gemcitabine in patients with metastatic or locally advanced urothelial cancer who have not received prior systemic therapy.
- Traitement de l’adénocarcinome prostatique métastatique symptomatique en phase d’hormono-indépendance : évaluation du rôle de la chimiothérapie sur la qualité de vie des patients : étude de phase III
- Adjuvant palbociclib as an alternative to chemotherapy for older patients with high risk luminal early breast cancer – Dr Etienne Brain
- Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer -Dr Etienne Brain
- a multicenter randomized phase II trial comparing the efficacy of a short hormone therapy in combination with radiotherapy to radiotherapy alone as a salvage treatment for patients with detectable PSA after radical prostatectomy.
- Intensified methotrexate, vinblastine, doxorubicin and cisplatin (I-MVAC) with or without panitumumab as first-line treatment of advanced urothelial carcinoma in patients without H-Ras nor K-Ras mutations. Randomised phase II study
- Randomized trial (GETUG 18) of dose escalation (80 vs 70 Gy) in high-risk prostate cancers combined with long-term androgen deprivation
- Randomized multicentric trial comparing an immediate adjuvant radiotherapy associated with short hormonotherapy by LH-RH (Décapeptyl® LP) analogue vs a delayed radiotherapy started at the biochemical relapse associated with short hormonotherapy by LH-RH (Décapeptyl® LP) analog in patients operated for a prostate cancer type pT3 R1 pN0 ou pNX, intermediate risk.
- A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents
- A prospective randomised phase III study of androgen deprivation therapy with docetaxel with or without local radiotherapy with or without abiraterone acetate and prednisone in patients with metastatic hormone-naïve prostate cancer.
- Randomised multi-centre study comparing the efficacy of short hormone therapy with Zoladex® concomitant to radiotherapy, versus radiotherapy alone, in treatment against prostate cancer biochemical recurrence after surgery.
- Multicentric randomized study evaluating the efficacy of a short hormone therapy prior to and concomitant with an exclusive conformal radiotherapy with curative aim for cancer localized to the prostate with intermediate prognosis
- Multicenter randomized phase III trial comparing hypo-fractioned versus standard radiotherapy in breast cancer with an indication for regional lymph node irradiation in terms of lymphedema occurrence
- Cohort study of prospective validation of predictive factors and biological imaging of response to bevacizumab (Avastin®) in combination with weekly paclitaxel chemotherapy in first line treatment patients with metastatic breast cancer
- An international investigator -led phase III multi arm multi stage multi center randomized controlled plateform trial of adjuvant therapy in patients with resected primary renal cell carcinoma at high or intermediate risk of relapse
- ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with one novel hormonal agent first line and non-progressive disease after second line treatment with a taxane: A multicenter randomize
- Prostate-cancer treatment using Stereotactic Radiotherapy for Oligometastases ablation in Hormone-naive patients - a GETUG-AFU Phase III randomized controlled trial
- Phase II study of concomitant and maintenance anti-PDL1 treatment with atezolizumab after chemoradiotherapy for muscle-infiltrating bladder cancer patients not eligible for radical cystectomy: Bladder Sparing
- PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients with Prostate Cancer after Prostatectomy
- AN OPEN LABEL, RANDOMIZED, PHASE III STUDY EVALUATING THE EFFICACY OF A COMBINATION OF APALUTAMIDE WITH RADIOTHERAPY AND LHRH AGONIST IN HIGH-RISK POST-PROSTATECTOMY BIOCHEMICALLY RELAPSED PROSTATE CANCER PATIENTS
- PHASE I/II MULTI-CENTER STUDY EVALUATING THE EFFICACY OF REPEAT STEREOTACTIC RADIATION IN PATIENTS WITH INTRAPROSTATIC TUMOR RECURRENCE AFTER EXTERNAL RADIATION THERAPY.
- PERSONALIZED TREATMENT OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER PATIENTS ACCORDING TO CIRCULATING TUMOR CELLS KINETIC DURING CHEMOTHERAPY
- A Phase II Safety Trial of Nivolumab in Patients with Metastatic Renal Cell Carcinoma Who Have Progressed During or After Prior Systemic Anti-Angiogenic Regimen
- Prospective phase II study of Gemcitabine plus platinium salt in combination with bevacizumab (Avastin®) for metastatic collecting duct carcinoma.
- PD-1 INHIBITOR AND CHEMOTHERAPY WITH CONCURRENT IRRADIATION AT VARIED TUMOUR SITES IN ADVANCED NON SMALL CELL LUNG CANCER
- ONCOBIOME: Exploitation of research results and the potential for application of the human microbiome in prediction, prevention and personalised treatment of disease”.
- A randomized phase II Study of Neoadjuvant Letrozole + Palbociclib versus sequential chemotherapy in Post-Menopausal Women with stage II-IIIA Luminal B Breast Cancer
- Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with metastatic cancer in response after 6 months of standard IO.
- A phase III randomised study of Exemestane vs placebo in postmenopausal women at increased risk of developing breast cancer.
- Single-arm study to de-escalate adjuvant endocrine therapy duration in women with HR+ HER2- breast cancer at very low risk of metastasis
- Isolated brain progression Treated with Tucatinib in addition to Pertuzumab and Trastuzumab
- ESSAI INTERNATIONAL, RANDOMISÉ, EN DOUBLE AVEUGLE, CONTRÔLÉ, COMPARANT LE TAMOXIFÈNE À L'ANASTROZOLE CHEZ LES FEMMES MÉNOPAUSÉES OPÉRÉES D'UN CARCINOME CANALAIRE IN SITU DU SEIN
- A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs)
- Phase Ib/II trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
- A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in patients with recurrent or metastatic head and neck cancer after failure of cisplatine, cetuximab and taxanes.
- Evaluation de la fréquence de l’infection par le Human PapillomaVirus dans les carcinomes amygdaliens et basi-linguaux
- Prevention of breast cancer by letrozole in post-menopausal women carrying a BRCA1/BRCA2 mutation
- Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
- Oligometastases of the LIVer treated with chemotherapy with or without Extracranial Stereotactic Body Radiation Therapy in patients with colorectal cancer
- Étude de phase III randomisée multicentrique en ouvert évaluant :
- l'administration conjointe de Docétaxel 75 mg/m2 et d'Épirubicine 75 mg/m2 versus FEC 100 dans le cancer du sein non métastatique avec envahissement ganglionnaire
- l'addition séquentielle d'Herceptin® chez les patientes [HER 2+++] ou [HER 2++ et FISH+].
- Etude de phase III évaluant l'apport du docétaxel au protocole FEC 100 dans le cancer du sein non métastatique avec envahissement ganglionnaire.
- Randomized trial of loco-regional radiotherapy added to Pembrolizumab versus Pembrolizumab alone for patients with newly diagnosed head and neck squamous cell carcinoma with synchronous metastases
- A phase II trial assessing Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in a pre-operative setting for resectable and untreated head and neck squamous cell carcinoma
- A multicentre, randomised , open label phase III trial to assess de-escalation of Post-Operative adjuvant treatment for HPV-positive tumours
- A multicenter, randomized, open label, phase II study evaluating the feasibility and tolerance of nivolumab neoadjuvant immunotherapy in high risk HPV driven Oropharynx Cancer.
- A Safety study of Nivolumab in Patients with Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- A Phase II, Multicenter, Non Randomized, Open Label Study of Nivolumab In Recurrent and/or Metastatic Salivary Gland Carcinoma of the Head and Neck
- A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse
- A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 therapy + Endocrine therapy vs. Anti-HER2 therapy + Endocrine therapy after induction treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
- Randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in estrogen receptor-positive, HER2-negative metastatic breast cancer patients
- Essai de phase II d’évaluation de l’efficacité et de la tolérance du Bévacizumab (Avastin®) dans les cancers du sein inflammatoire HER2-. 2
- Essai de phase II d’évaluation de l’efficacité et de la tolérance du Bévacizumab (Avastin®) dans les cancers du sein inflammatoire HER2-.
- Randomized, open label, multicentric phase III trial evaluating the benefit of a sequential regimen associating FEC100 and Ixabepilone in adjuvant treatment of non metastatic, poor prognosis breast cancer defined as triple-negative tumor [HER2 negative - ER negative - PR negative] or [HER2 negative and PR negative] tumor; in node positive or node negative patients
- MINDACT (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy): A prospective, randomized study comparing the 70-gene signature with the common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes.
- Étude de phase III randomisée évaluant la durée optimale d'une chimiothérapie de type FEC 100 : 6 cycles versus 4 cycles dans le cancer du sein sans envahissement ganglionnaire.
- Association of Radiochemotherapy and Immunotherapy for the treatment of unresectable Oesophageal caNcer: a comparative randomized phase II trial
- A Phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in Metastatic Pancreatic Ductal Adenocarcinoma
- Randomized phase III trial comparing concurrent chemoradiation and adjuvant chemotherapy with pelvic radiation alone in high risk and advanced stage endometrial carcinoma
- A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive, HER2-negative resected locoregional recurrence of breast cancer
- Trastuzumab (T) and pertuzumab (P) compared to trastuzumab pertuzumab combined with chemotherapy (C) both followed by T-DM1 in case of progression– a randomized phase 2 trial.
- Phase III study evaluating palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy 2
- Essai de phase III évaluant l'intérêt d'une chimiothérapie d'entretien associant DOCETAXEL (TAXOTERE®) 5-FU après traitement d'induction par chimiothérapie intensifiée dans les cancers du sein inflammatoires.
- A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III
- Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic breast cancer
- Etude de phase III randomisée comparant une hormonothérapie adjuvante standard +/- chimiothérapie chez des patientes atteintes de cancer du sein localisé avec 1-3 N+, RH+ et Her2- dont le score de rechute selon Oncotype DX™ est inférieur ou égal à 25
- A phase II study to assess the efficacy of rucaparib in metastatic breast cancer patients with a BRCAness genomic signature
- Phase III multicentric trial comparing accelerated partial breast irradiation (APBI) versus standard or hypofractionated whole breast irradiation in low risk of local recurrence of breast cancer
- Radiation dose intensity study in breast cancer in young women: a randomized phase III trial of additional dose to the tumor bed
- ROMANCE: Prospective study of omission of whole-breast radiotherapy following breast-conserving surgery in patients with very low risk ductal carcinoma in situ of the breast
- Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: A phase II randomized study of the UNICANCER-AFSOS Supportive Care Intergroup.
- Strategy adapted to the prognosis for the use of dosedense chemotherapy in patients with disseminated non-seminomatous germ tumors of poor prognosis: phase III trial
- Feasibility and efficacy of standardized APA in patients receiving oral therapy for metastatic cancer
- Randomised multi-centre study comparing the efficacy of short hormone therapy with Zoladex® concomitant to radiotherapy, versus radiotherapy alone, in treatment against prostate cancer biochemical recurrence after surgery.
- Multicentric phase II study evaluating the efficacy of Gemcitabine in combination with Pazopanib as a second-line treatment for uterine leiomyosarcomas or metastatic or relapsed soft tissue carcinoma.
- A phase III randomized study evaluating surgery of residual disease in patients with
metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.
- Intergroup Study ( SFCE/GSF-GETO) OS2006 - Zoledronate Osteosarcoma Treatment Protocol for osteosarcoma of the child , adolescent and adult including: A randomized trial and biological studies
- Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery
- Multicentric phase I / II study evaluating the efficacy and toxicity of imatinib in adult patients with aggressive fibromatosis who cannot be treated by surgery or curative radiotherapy.
- Phase II study of the Cis-platinum + VP16 combination in patients with refractory or relapsing Ewing (or related) tumors
- Multicentric Phase III Randomized Clinical Protocol Comparing Consolidation by High Dose Chemotherapy with Continuation of Conventional Chemotherapy in Adult Soft Tissue Sarcomas in Partial or Complete Response After 4 MAID Cures
- Ewing's tumor treatment protocol: randomized trials with comparison of consolidation chemotherapy including a medico-economic evaluation
- Identification of the molecular alterations associated with resistance to endocrine therapy and impacting treatment with mTOR inhibitor of HR+ metastatic breast cancer in post-menopausal women
- Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic non-small cell lung cancer.
- SAFIRPI3K: a phase II randomized trial testing Alpelisib as maintenance therapy in patients with PIK3CA mutated advanced breast cancer
- Détermination du spectre tumoral, évaluation de la pénétrance et de l’utilité clinique des mutations constitutionnelles de nouveaux gènes de prédisposition aux cancers du sein et de l’ovaire
- TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC)
- Tracking triple-negative breast cancer evolution through therapy
- A randomized phase III Trial comparing conventional-dose chemotherapy using PACLITAXEL, IFOSFAMIDE, and CISPLATIN (TIP) with high-dose chemotherapy using mobilizing PACLITAXEL PLUS IFOSFAMIDE followed by high-dose CARBOPLATIN AND ETOPOSIDE (TI-CE) as first
- AI-driven quality insurance for delineation in radiotherapy breast clinical trials
- Extracranial Stereotactic Body Radiation Therapy (SBRT) added to standard treatment versus standard treatment alone in solid tumors patients with between 1 and 3 bone-only metastases
- Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment
- Randomised Phase 2 trial of mepact combined with post-operative chemotherapy for newly diagnosed high risk osteosarcoma (metastatic or localized disease with poor histologic response)
- A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus fulvestrant versus standard endocrine therapy in patients with ER positive HER2 negative breast cancer
- Evaluation de la fréquence de l’infection par le Human PapillomaVirus dans les carcinomes amygdaliens et basi-linguaux 3
- Evaluation de la fréquence de l’infection par le Human PapillomaVirus dans les carcinomes amygdaliens et basi-linguaux 2
- Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease
- ULTIMATE trial: UnLock The IMmune cells ATtraction in ER+ breast cancers
- A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colorectal metastases considered still non resectable after at least two months of systemic induction chemotherapy: SULTAN (improving SUrgery of Liver metastases: a Trial of the Arterial chemotherapy Network)
- A Phase III, Randomised, international trial comparing mFOLFIRINOX triplet chemotherapy to mFOLFOX for high-risk stage III colon cancer in adjuvant setting
- Interest of adjuvant chemotherapy in patients with CINSARC high-risk localized resected uterine leiomyosarcoma
- Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, platform phase 3 trial
- A ctDNA screening program in patients with HR+, HER2 negative metastatic breast cancer for detection of high-risk relapse patients on any CDK4/6 inhibitor and a randomised phase II study comparing alpelisib combined with fulvestrant to ribociclib combined with fulvestrant, in patients with persistent targetable PIK3CA mutations
Programs
